Slingshot members are tracking this event:

FDA Approves Expanded Indication for Merck’s KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma; KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 18, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Melanoma, Fda, Aproval, Keytruda, Pembrolizumab